Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand

Lancet

Volumn 348, Issue 9029, 1996, Pages 701-707

  Nosten, François ^a,b,f   Luxemburger, Christine ^a,b   Kyle, Dennis E ^c   Ballou, W Ripley ^d   Wittes, Janet ^e   Wah, Eh ^a   Chongsuphajaisiddhi, Tan ^b   Gordon, Daniel M ^d   White, Nicholas J ^a,b,f   Sadoff, Jerald C ^d   Heppner, D Gray ^c  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e University of Iowa   (United States)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ALLERGIC REACTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INCIDENCE; MALARIA FALCIPARUM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THAILAND;

EID: 9544237169     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)04465-0     Document Type: Article

References (21)

1. Moreno A, Patarroyo ME. Malaria vaccines. Curr Opin Immunol 1995; 7: 607-11.
2. Riley E. Malaria vaccine trials: SPf66 and all that. Curr Opin Immunol 1995; 7: 612-16.
3. Alonso PL, Smith T, Armstrong Schellenberg JRM, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344: 1175-81.
4. D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995; 346: 462-67.
5. Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum in Colombia. Lancet 1993; 341: 705-10.
6. Luxemburger C, Kyaw LT, White NJ, et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 1996; 90: 105-11.
7. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug resistant P falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170: 971-77.
8. Ballou WR, Blood JC, Chongsuphajaissidhi T, et al. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study, Parasitol 1995; 110: S25-36.
9. Hayashi J, Nakashima K, Noguchi Aet al. Cost effectiveness of intradermal versus subcutaneous hepatitis B vaccination for the mentally handicapped. J Infect. 23:1991;39-45.
10. World Health Organization Division of Control of Tropical Diseases Severe and complicated malaria, 2nd ed. Trans R Soc Trop Med Hyg. 84((suppl 2)):1990;1-65.
11. Luxemburger C, Nosten F, Raimond D, et al. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Am J Trop Med Hyg 1995; 53: 522-25.
12. Gordon DM, Duffy PE, Heppner DGet al. Phase 1 safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under cGMP conditions in the United States. Am J Trop Med Hyg. 55:1996;63-68.
13. Borland Company, dBASE IV: Language Reference. 1992.
14. SAS v. 6.08. SAS Institute, Cary, NC, 1995.
15. Efron B, Tibshirani R Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statist Sci. 1:1986;54-77.
16. Patarroyo ME, Amador R, Clavijo P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988; 332: 158-61.
17. Amador R, Moreno A, Murillo LA, et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 1992; 166: 139-44.
18. Nosten F, Luxemburger C, Kyle D, et al. Phase I trial of the SPf66 malaria vaccine in a malaria experienced population in Southeast Asia. Am J Trop Med Hyg (in press).
19. Patarroyo G, Franco L, Amador R, et al. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 1992; 10: 175-78.
20. Rocha CL, Murillo LA, Mora ALet al. Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf66. Parasite Immunol. 14:1992;95-109.
21. Salcedo M, Barreto L, Rojas M, Moya R, Cote J, Patarroyo ME. Studies on the humoral immune response to synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol 1991; 84: 122-28.